206 related articles for article (PubMed ID: 34257566)
1. Identification of Key Genes Involved in Pancreatic Ductal Adenocarcinoma with Diabetes Mellitus Based on Gene Expression Profiling Analysis.
Zhou W; Wang Y; Gao H; Jia Y; Xu Y; Wan X; Zhang Z; Yu H; Yan S
Pathol Oncol Res; 2021; 27():604730. PubMed ID: 34257566
[TBL] [Abstract][Full Text] [Related]
2. Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2016 Aug; 39(4):379-88. PubMed ID: 27240826
[TBL] [Abstract][Full Text] [Related]
3. Identification of hub genes and regulators associated with pancreatic ductal adenocarcinoma based on integrated gene expression profile analysis.
Shang M; Zhang L; Chen X; Zheng S
Discov Med; 2019 Sep; 28(153):159-172. PubMed ID: 31926587
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis.
Zhou J; Hui X; Mao Y; Fan L
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31311829
[TBL] [Abstract][Full Text] [Related]
5. Construction of a prognostic prediction system for pancreatic ductal adenocarcinoma to investigate the key prognostic genes.
Zheng B; Peng J; Mollayup A; Bakri A; Guo L; Zheng J; Xu H
Mol Med Rep; 2018 Jan; 17(1):216-224. PubMed ID: 29115420
[TBL] [Abstract][Full Text] [Related]
6. Analysis of global gene expression profiles suggests a role of acute inflammation in type 3C diabetes mellitus caused by pancreatic ductal adenocarcinoma.
Gao W; Zhou Y; Li Q; Zhou Q; Tan L; Song Y; Zhao X; Yu M; Zheng S; Ye H; Zeng B; Lin Q; Zhou J; Liu Y; Huang H; Zhang H; Hu X; Li Z; Dai X; Chen R
Diabetologia; 2015 Apr; 58(4):835-44. PubMed ID: 25636208
[TBL] [Abstract][Full Text] [Related]
7. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
9. Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma.
Luan H; Zhang C; Zhang T; He Y; Su Y; Zhou L
Dis Markers; 2020; 2020():8825997. PubMed ID: 32934754
[TBL] [Abstract][Full Text] [Related]
10. Identification of differentially expressed genes in pancreatic ductal adenocarcinoma and normal pancreatic tissues based on microarray datasets.
Liu L; Wang S; Cen C; Peng S; Chen Y; Li X; Diao N; Li Q; Ma L; Han P
Mol Med Rep; 2019 Aug; 20(2):1901-1914. PubMed ID: 31257501
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive meta-analysis of transcriptome data to identify signature genes associated with pancreatic ductal adenocarcinoma.
Kordshouli SO; Tahmasebi A; Moghadam A; Ramezani A; Niazi A
PLoS One; 2024; 19(2):e0289561. PubMed ID: 38324544
[TBL] [Abstract][Full Text] [Related]
12. PDAC-ANN: an artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression.
Almeida PP; Cardoso CP; de Freitas LM
BMC Cancer; 2020 Jan; 20(1):82. PubMed ID: 32005189
[TBL] [Abstract][Full Text] [Related]
13. Gene signature and connectivity mapping to assist with drug prediction for pancreatic ductal adenocarcinoma.
Xiao Y; Zhang B; Cloyd JM; Xu G; Du S; Mao Y; Pawlik TM
Surg Oncol; 2022 Sep; 44():101849. PubMed ID: 36116415
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatic Analysis Suggests That Three Hub Genes May Be a Vital Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.
Chang X; Yang MF; Fan W; Wang LS; Yao J; Li ZS; Li DF
J Comput Biol; 2020 Nov; 27(11):1595-1609. PubMed ID: 32216644
[TBL] [Abstract][Full Text] [Related]
15. Potential four‑miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co‑expression analysis.
You L; Wang J; Zhang F; Zhang J; Tao H; Zheng X; Hu Y
Mol Med Rep; 2019 Jan; 19(1):441-451. PubMed ID: 30483731
[TBL] [Abstract][Full Text] [Related]
16. Identification of key regulators of pancreatic ductal adenocarcinoma using bioinformatics analysis of microarray data.
Li N; Zhao X; You S
Medicine (Baltimore); 2019 Jan; 98(2):e14074. PubMed ID: 30633213
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of metabolic pathways could offset the poor prognosis conferred by co-existent diabetes mellitus in pancreatic (head) adenocarcinoma.
Gardi N; Ketkar M; McKinnon RA; Pandol SJ; Dutt S; Barreto SG
ANZ J Surg; 2021 Nov; 91(11):2466-2474. PubMed ID: 34514690
[TBL] [Abstract][Full Text] [Related]
18. IL2RA is a prognostic indicator and correlated with immune characteristics of pancreatic ductal adenocarcinoma.
Fan L; Wang X; Chang Q; Wang Y; Yang W; Liu L
Medicine (Baltimore); 2022 Oct; 101(42):e30966. PubMed ID: 36281157
[TBL] [Abstract][Full Text] [Related]
19. Possible Molecular Markers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.
Shen Q; Yu M; Jia JK; Li WX; Tian YW; Xue HZ
Med Sci Monit; 2018 Apr; 24():2368-2376. PubMed ID: 29671412
[TBL] [Abstract][Full Text] [Related]
20. A competing endogenous RNA network identifies novel mRNA, miRNA and lncRNA markers for the prognosis of diabetic pancreatic cancer.
Yao K; Wang Q; Jia J; Zhao H
Tumour Biol; 2017 Jun; 39(6):1010428317707882. PubMed ID: 28639886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]